Method of treating CD4+ T cell lymphopenia in immuno-compromised patients
US5728560A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 14, 1996 |
| Grant date | Mar 17, 1998 |
| Priority date | — |
| Expiry date | Jun 14, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y305/04004
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to methods of treating CD4+ T cell lymphopenia in HIV-infected patients. The methods include administering an effective mount of adenosine deaminase or related enzymatic material to a patient in need thereof. In preferred aspects of the invention, the method is employed in conjunction with HIV-infected patients having CD4+ T cell levels of less than about 200/.mu.l. Effective amounts of the enzyme range from about 5 to about 50 IU/kg/week. In one particularly preferred aspect of the invention, the adenosine deaminase is conjugated to one or more strands of polyethylene glycol to prolonged activity in vivo.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.